hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06366321, orgStudyIdInfo id: 23-067, briefTitle: Using Digital Technology Versus Conventional Relining Procedure for Correction of Loose Maxillary Complete Denture, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-01-23, completionDateStruct date: 2024-02-01, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: British University In Egypt, class: OTHER, descriptionModule briefSummary: This study aimed to evaluate the use of computer added designning / computer added manufacturing (CAD/ CAM ) technology versus conventional relining procedure for treating ill-fitted loose maxillary complete denture and its effect on patient satisfaction, denture retention, and denture adaptation to oral tissues., conditionsModule conditions: Dental Diseases, conditions: Dental Trauma, conditions: Bone Remodeling Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 12, type: ACTUAL, armsInterventionsModule interventions name: relining technique, interventions name: CAD/CAM milling technique, outcomesModule primaryOutcomes measure: patient satisfaction using questionnaire, primaryOutcomes measure: denture retention, primaryOutcomes measure: denture adaptation to oral tissues, eligibilityModule sex: ALL, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: British University in Egypt, city: El Shorouk, state: Cairo, zip: 4914085, country: Egypt, geoPoint lat: 30.13806, lon: 31.61556, hasResults: False
protocolSection identificationModule nctId: NCT06366308, orgStudyIdInfo id: ProBiox, briefTitle: Decade-Long Insights Into Transperineal Prostate Biopsy in a West China Population, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-05-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: West China Hospital, class: OTHER, descriptionModule briefSummary: Prostate cancer (PCa) remains one of the most prevalent malignancies affecting men globally. The disease spectrum of PCa ranges from indolent tumors, which may require minimal to no intervention, to aggressive, potentially lethal forms. The complexity of PCa underscores the critical need for precise diagnostics, as early and accurate detection is key to improving patient outcomes and tailoring appropriate treatment strategies. There have been remarkable advancements in biopsy technology. Significant strides in magnetic resonance imaging (MRI), especially with the establishment of the Prostate Imaging Reporting and Data System (PI-RADS), have substantially improved the accuracy of PCa detection. The combination of MRI with traditional biopsy methods, including MRI-targeted biopsy (MRI-TBx) and systematic biopsy (SBx), also marks a major advancement in the field.Despite advances in PCa detection, the need for improving diagnostics and in-depth assessment of the latest PBx techniques through extensive, longitudinal studies remains critical. Besides, based on the world health organization (WHO) classification, PCa includes a range of pathological forms beyond the commonly known acinar adenocarcinoma. However, the prevalence and demographic distribution of non-adenocarcinoma types, as well as the characteristics of patients with these rarer forms, remain unclear. Leveraging PBx records spanning over 10 years and involving 10,038 cases, this study aims to shed light on temporal trends in PBx positivity, the evolving clinical profiles of PCa patients, and the differences in clinicopathological characteristics of PCa between Western and Asian populations., conditionsModule conditions: Prostate Cancer, conditions: Pathology, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 10000, type: ESTIMATED, armsInterventionsModule interventions name: Transperineal Prostate Biopsy, outcomesModule primaryOutcomes measure: Positive rate of prostate biopsy, eligibilityModule sex: MALE, minimumAge: 40 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06366295, orgStudyIdInfo id: WUM.Perio.05, briefTitle: Comparison of Subgingival Mechanotherapy With and Without the Use of a Perioscope: Clinical Trial, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-11, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Medical University of Warsaw, class: OTHER, descriptionModule briefSummary: The study aims to comparatively assess clinical parameters, biochemical and microbiological parameters after treatment of periodontitis using subgingival mechanotherapy traditional and subgingival mechanotherapy using a perioscope., conditionsModule conditions: Periodontitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 26, type: ESTIMATED, armsInterventionsModule interventions name: subgingival mechanotherapy with perioscopy, interventions name: classical subgingival mechanotherapy, outcomesModule primaryOutcomes measure: Probing pocket depth (PPD), primaryOutcomes measure: Clinical attachment level (CAL), primaryOutcomes measure: Bleeding on probing (BoP), primaryOutcomes measure: Plaque index (PI), secondaryOutcomes measure: Width of keratinized tissue (KTW), secondaryOutcomes measure: Gingival thickness (GT), otherOutcomes measure: Subgingival plaque pathogens (Aa, Pg, Td) levels, otherOutcomes measure: Gingival crevicular fluid levels of cytokines, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Department of Periodontology and Oral Mucosa Diseases, Medical University of Warsaw, status: RECRUITING, city: Warsaw, state: Mazowieckie, zip: 02-097, country: Poland, contacts name: Bartlomiej Gorski, DDS, PhD, role: CONTACT, phone: +48 22 502 20 99, email: bartlomiej.gorski@wum.edu.pl, geoPoint lat: 52.22977, lon: 21.01178, hasResults: False
protocolSection identificationModule nctId: NCT06366282, orgStudyIdInfo id: IRB00110030, briefTitle: Pediatric and Caregiver Traumatic Stress Intervention (PACTS), acronym: PACTS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Wake Forest University Health Sciences, class: OTHER, collaborators name: Childress Institute for Pediatric Trauma, descriptionModule briefSummary: The purpose of this study is to learn more about how to help the caregiver and child survivor of a traumatic injury handle post-traumatic stress disorder and/or depression., conditionsModule conditions: Traumatic Injury, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Caregiver Counseling for Childhood Traumatic Injury, interventions name: Standard of Care for Childhood Traumatic Injury, outcomesModule primaryOutcomes measure: Change in Kessler 6 Scores, primaryOutcomes measure: Change in Patient Health Questionnaire - 9 (PHQ-9) Scores, primaryOutcomes measure: Change in Child and Adolescent Trauma Screen (CATS) Scores, eligibilityModule sex: ALL, minimumAge: 1 Year, maximumAge: 6 Years, stdAges: CHILD, contactsLocationsModule locations facility: Wake Forest University Health Sciences, city: Winston-Salem, state: North Carolina, zip: 27157, country: United States, contacts name: Elizabeth White, MA, LCMHCS, role: CONTACT, phone: 336-716-2801, email: ebwhite@wakehealth.edu, contacts name: Elizabeth Shilling, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 36.09986, lon: -80.24422, hasResults: False
protocolSection identificationModule nctId: NCT06366269, orgStudyIdInfo id: STUDY20240374, briefTitle: Acupuncture First for IC/BPS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: David Sheyn, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to learn if acupuncture in addition to behavioral changes can better treat in women with bladder pain syndrome (also known as interstitial cystitis) that have not received other treatments. The main question it aims to answer is:Does acupuncture improve pain symptoms on the Interstitial Cystitis Index? Researchers will compare six (6) weeks behavioral management alone to behavioral management and acupuncture.Participants will* complete surveys about their bladder pain symptoms* make behavioral changes that have been shown to improve bladder pain symptoms* attend six (6) weekly acupuncture sessions* attend six (6) weekly physical therapy sessions after finishing acupuncture, conditionsModule conditions: Bladder Pain Syndrome, conditions: Interstitial Cystitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Group allocation will be masked to the care provider and investigators only while participants undergo the initial 6 weeks of treatment. Due to the nature of the intervention (acupuncture) participants are not able to be blinded., whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 34, type: ESTIMATED, armsInterventionsModule interventions name: Acupuncture, interventions name: Behavioral management, interventions name: Physical therapy, outcomesModule primaryOutcomes measure: O'Leary-Sant Interstitial Cystitis Index (OLSICI), secondaryOutcomes measure: Patient Global Impression of Improvement (PGI-I), secondaryOutcomes measure: Short Form (SF-36), secondaryOutcomes measure: Genitourinary Pain Index (GUPI), secondaryOutcomes measure: Number of additional treatments used during study period, secondaryOutcomes measure: Number of unscheduled interactions, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 89 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06366256, orgStudyIdInfo id: 1R01DC017301-01, type: NIH, link: https://reporter.nih.gov/quickSearch/1R01DC017301-01, briefTitle: Simplified Ultrasound Feedback for Speech Remediation, acronym: SUFSR, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-24, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: University of Cincinnati, class: OTHER, descriptionModule briefSummary: Recent research in motor control shows that people learn new movements best when they receive feedback external to the body. Traditional ultrasound speech therapy works well for many children, but involves teaching children to focus on their internal tongue movements. The goal of the study is to test whether ultrasound biofeedback delivered without showing children a display of their tongue movements will be effective as a treatment for residual speech sound disorders in children. We focus on children who have trouble producing the sound "r" as in "rabbit". The first aim is to develop a fast reliable system to track movements of different parts of the tongue using ultrasound and to identify which combinations of movements will produce a good "r" and which do not. The second aim is to develop a motivational game in which children receive feedback on the success of their tongue movements by what happens to an animated character on a screen. This developed version of ultrasound feedback therapy will be compared to the traditional version of ultrasound feedback therapy to determine how the two approaches can best be utilized in the clinic., conditionsModule conditions: Speech Sound Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Traditional ultrasound biofeedback, interventions name: Simplified ultrasound biofeedback, outcomesModule primaryOutcomes measure: Change in percent accurate words in probe list at beginning and midpoint of study, primaryOutcomes measure: Change in percent accurate words in probe list at beginning and end of study, eligibilityModule sex: ALL, minimumAge: 7 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: University of Cincinnati, status: RECRUITING, city: Cincinnati, state: Ohio, zip: 45220, country: United States, contacts name: Suzanne E Boyce, PhD, role: CONTACT, phone: 513-558-8509, email: boycese@ucmail.uc.edu, contacts name: Sarah M Dugan, PhD, role: CONTACT, email: hamilsm@ucmail.uc.edu, geoPoint lat: 39.12713, lon: -84.51435, hasResults: False
protocolSection identificationModule nctId: NCT06366243, orgStudyIdInfo id: CVL-231-HV-1012, briefTitle: A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-10, primaryCompletionDateStruct date: 2024-06-24, completionDateStruct date: 2024-06-24, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Cerevel Therapeutics, LLC, class: INDUSTRY, descriptionModule briefSummary: The primary purpose of this study is to evaluate the potential of gastric pH-dependent drug-drug interaction effect of esomeprazole, a proton pump inhibitor (PPI), on the pharmacokinetics (PK) of emraclidine in healthy adult participants., conditionsModule conditions: Healthy Participants, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Emraclidine, interventions name: Esomeprazole, outcomesModule primaryOutcomes measure: Maximum Observed Plasma Concentration (Cmax) of Emraclidine, primaryOutcomes measure: Time to Maximum (Peak) Plasma Concentration (Tmax) of Emraclidine, primaryOutcomes measure: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUC0-t) of Emraclidine, primaryOutcomes measure: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Emraclidine, secondaryOutcomes measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs), secondaryOutcomes measure: Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Values, secondaryOutcomes measure: Number of Participants With Clinically Significant Changes in Vital Sign Parameters, secondaryOutcomes measure: Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments, secondaryOutcomes measure: Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results, secondaryOutcomes measure: Changes in Suicidality Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06366230, orgStudyIdInfo id: 24-41450, briefTitle: Adding Urea to the Final Dialysis Fluid, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2028-06-30, completionDateStruct date: 2028-06-30, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: University of California, San Francisco, class: OTHER, descriptionModule briefSummary: At times patients with advanced renal failure present with severe hyperkalemia or acidosis and very high serum blood urea nitrogen (BUN) concentrations. These patients cannot be dialyzed aggressively as the lowering of serum BUN may results in disequilibrium syndrome but on the other hand they need aggressive dialysis in order to lower their serum potassium or fix their severe acidosis. If one is able to add urea to the dialysis fluid, one can prevent the rapid lowering of serum BUN and osmolality at the same time as doing aggressive dialysis to lower serum potassium and/or fix the metabolic acidosis., conditionsModule conditions: Dysequilibrium Syndrome, conditions: ESRD, conditions: Hyperkalemia, conditions: Metabolic Acidosis, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Urea in the dialysate, outcomesModule primaryOutcomes measure: Disequilibrium, primaryOutcomes measure: Serum potassium concentration, primaryOutcomes measure: Serum CO2 concentration, secondaryOutcomes measure: Serum BUN concentration, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zuckerberg San Francisco General Hospital, city: San Francisco, state: California, zip: 94110, country: United States, contacts name: Ramin Sam, MD, role: CONTACT, phone: 628-206-6605, email: ramin.sam@ucsf.edu, geoPoint lat: 37.77493, lon: -122.41942, hasResults: False
protocolSection identificationModule nctId: NCT06366217, orgStudyIdInfo id: 20-32530A, briefTitle: Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: University of California, San Francisco, class: OTHER, descriptionModule briefSummary: To raise the standard of care, improve the overall patient experience and streamline practice flow, Eyenovia has developed an innovative mydriatic to be delivered as a microdose by a specialized dispenser. While still achieving effective pupil dilation, MydCombi has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery. The proposed study hopes to demonstrate the non-inferiority of using MydCombi to achieve pupillary dilation in patients compared to standard of care eye drops., conditionsModule conditions: Dilation, conditions: Pupil Reaction Absent, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: MydCombi Device, interventions name: MydCombi Drug, outcomesModule primaryOutcomes measure: Percent change in Spherical equivalent, primaryOutcomes measure: Percent Change in maximum pupil diameter, primaryOutcomes measure: Percent Change in pupil constriction percentage, secondaryOutcomes measure: Percent Change in Intraocular Pressure, eligibilityModule sex: ALL, minimumAge: 2 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of California, San Francisco, city: San Francisco, state: California, zip: 94143, country: United States, geoPoint lat: 37.77493, lon: -122.41942, hasResults: False
protocolSection identificationModule nctId: NCT06366204, orgStudyIdInfo id: H23-03119, briefTitle: Lysine Requirements During Lactation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-15, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: University of British Columbia, class: OTHER, collaborators name: Canadian Institutes of Health Research (CIHR), descriptionModule briefSummary: The study aims to establish lysine requirements using the indicator amino acid oxidation (IAAO) method in women exclusively breastfeeding a single infant aged 3-4 months, and how maternal lysine needs change once infant transition to complimentary feeding at a later age of 9-10 months. Each 8-hour study day will have an assigned test lysine intake ranging from deficient to excess. The diets will be provided in a complete protein shake format, meeting all nutrient requirements except for the test lysine intake. Breath samples evaluate the indicator's oxidation to determine protein synthesis in response to lysine intake. Urine and one blood sample will be collected to assess metabolite concentrations., conditionsModule conditions: Lactation, conditions: Breastfeeding, Exclusive, conditions: Breastfeeding, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Single day interventions; Repeated measures design., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Dietary Lysine Intakes, outcomesModule primaryOutcomes measure: Carbon 13 Oxidation, eligibilityModule sex: FEMALE, minimumAge: 20 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: BC Children's Hospital Research Institute, status: RECRUITING, city: Vancouver, state: British Columbia, zip: V5Z 4H4, country: Canada, contacts name: Taylor Bailey, BSc, role: CONTACT, phone: 705-698-7648, email: taylor.bailey@bcchr.ca, contacts name: Rajavel Elango, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 49.24966, lon: -123.11934, hasResults: False